Condition: Muscular Ventricular Septal Defect · Sponsor: Occlutech International AB
The Occlutech® mVSD is indicated for percutaneous occlusion of hemodynamically or clinically significant muscular ventricular septal defects. The objectives of the study are: * To confirm the efficacy of Occlutech mVSD in patients requiring transcatheter occlusion (closure) of muscular ventricular septal defects. * To confirm the safety of Occlutech mVSD in patients requiring transcatheter occlusion (closure) of muscular ventricular septal defects.
This description comes directly from the study's public registry record.
Ahmed Della · +49 151 14139961 · ahmed.dellaa@occlutech.com
Always discuss trial participation with your own doctor first.
| Children's Health Ireland | Dublin, Ireland | Not Yet Recruiting |
| İzmir Şehir Hastanesi | Izmir, Bayraklı, Turkey (Türkiye) | Not Yet Recruiting |
| Eskişehir Osmangazi Üniversite Hastanesi | Eskişehir, Odunpazarı, Turkey (Türkiye) | Not Yet Recruiting |
| Dicle Üniversitesi Tıp Fakültesi Hastanesi | Diyarbakır, Sur, Turkey (Türkiye) | Not Yet Recruiting |
| Gaziantep Unıversıty Hospital | Gaziantep, Şehitkamil, Turkey (Türkiye) | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05329350